Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07124702 · ClinicalTrials.gov registry record · NA

Cessation of Dual Use of Cigarettes and E-cigarettes During Pregnancy

A NA study of Gestational Weight Gain and Dual Use of Cigarettes and E-cigarettes, sponsored by State University of New York at Buffalo.

Recruiting
Registry status
NA
Development phase
45
Enrollment target
1
Study location

NCT07124702: Recruiting NA study of Gestational Weight Gain and Dual Use of Cigarettes and E-cigarettes, sponsored by State University of New York at Buffalo.

NCT07124702 is a NA study of Gestational Weight Gain and Dual Use of Cigarettes and E-cigarettes that is actively recruiting participants, run by State University of New York at Buffalo. The registered enrollment target is 45 participants, below the 487-participant average among 7 other Gestational Weight Gain trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07124702, a NA study of Gestational Weight Gain and Dual Use of Cigarettes and E-cigarettes, is actively recruiting participants, sponsored by State University of New York at Buffalo.

RECRUITING
Registry status
NA
Development phase
45 participants
Enrollment target
1
Study location

Study Summary

We propose a randomized controlled trial to develop and evaluate a cessation program with two different strategies for dual users during pregnancy. We plan to enroll 45 pregnant mothers (≤20 gestational weeks) with low household incomes from the Western NY region. To be eligible, they must be currently dual using CCs and nicotine-containing ECs. These mothers will be randomized into one of three groups: 1) simultaneous cessation intervention group (N=15), 2) stepwise cessation intervention group (N=15), and 3) control group (N=15). We hypothesize that nicotine abstinence rates at 8 weeks after randomization will be higher in the intervention groups than in the control group.

Primary Outcome

Research staff who are blinded to the participant's group assignment will administer a timeline follow-back interview (trained by the PI, Dr. Wen) to assess the participant's recent smoking and vaping history. Based on self-reports, we will classify smoking and vaping status in the past 7 days (7-day point prevalence) prior to the outcome assessment visits at pre-test, 8 weeks after randomization, and at the end of pregnancy. To confirm self-reported complete nicotine abstinence (i.e., abstinenc

Conditions Studied

Gestational Weight Gain Dual Use of Cigarettes and E-cigarettes Birth-weight-for-gestational-age z Score

Interventions

  • BEHAVIORAL Simultaneous cessation intervention
  • BEHAVIORAL Stepwise cessation intervention
  • BEHAVIORAL Behavior counseling only

Study Locations (1)

New York

  • State University of New York at Buffalo - Buffalo

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2025-10-01
Est. Completion 2027-03-31
Phase NA
State University of New York at Buffalo

243 total trials

What NCT07124702 shows while recruiting

NCT07124702 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 487-participant average among 7 other Gestational Weight Gain trials with a reported enrollment target (91% lower).

The record links to 3 conditions, with Gestational Weight Gain appearing as the primary indexed condition, and to 3 interventions - of which Simultaneous cessation intervention is the first listed.

NCT07124702 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT07124702 about?

NCT07124702 is a clinical study titled "Cessation of Dual Use of Cigarettes and E-cigarettes During Pregnancy". We propose a randomized controlled trial to develop and evaluate a cessation program with two different strategies for dual users during pregnancy. We plan to enroll 45 pregnant mothers (≤20 gestational weeks) with low household incomes from the Western NY region. To be eligible, they must be curren...

What is the current status of trial NCT07124702?

This trial is currently recruiting. It is a NA study. The enrollment target is 45 participants. The study started on 2025-10-01. Estimated completion is 2027-03-31.

What conditions does trial NCT07124702 study?

This clinical trial studies the following conditions: Gestational Weight Gain, Dual Use of Cigarettes and E-cigarettes, Birth-weight-for-gestational-age z Score.

What interventions are being tested in trial NCT07124702?

The interventions under investigation include: Simultaneous cessation intervention (BEHAVIORAL), Stepwise cessation intervention (BEHAVIORAL), Behavior counseling only (BEHAVIORAL).

Who is sponsoring clinical trial NCT07124702?

This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07124702 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gestational Weight Gain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00804154 · 45 participants · Phase 1

    Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

  • NCT01851694 · 45 participants · NA

    Beta-cell Response to Incretin Hormones in Cystic Fibrosis

  • NCT02896335 · 45 participants · Phase 2

    Palbociclib and Pembrolizumab In Central Nervous System Metastases

  • NCT03454035 · 45 participants · Phase 1

    Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07124702

Source: ClinicalTrials.gov NCT07124702, the US trial registry maintained by the National Library of Medicine. NCT07124702 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.